# Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

> **NCT00652041** · PHASE4 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Thalidomide
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00652041
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652041, "Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00652041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*